Article info

Download PDFPDF

330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA
Free

Authors

Citation

Otify M, Laios A, Elkadi H, et al
330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA

Publication history

  • First published December 4, 2020.
Online issue publication 
February 04, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.